Clinical trial EPIK-O
A Phase III, multi-center, randomized (1:1), open-label, activecontrolled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer (EPIK-O / CBYL719K12301)
| Cancers | |
|---|---|
| Organ | Ovary |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Novartis |
| EudraCT Identifier | 2019-004682-40 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04729387 |
| Last update |